Literature DB >> 512893

High-pressure liquid chromatographic assay for hydralazine in human plasma.

T M Ludden, L K Goggin, J L McNay, K D Haegele, A M Shepherd.   

Abstract

A specific high-performance liquid chromatographic assay for hydralazine in human plasma was developed. Plasma hydralazine is reacted with 10 microliter of p-anisaldehyde for 7 min at room temperature to form hydralazine p-anisaldehyde hydrazone. This derivative is extracted into ethyl acetate, and the solvent is removed by evaporation. The residue is reconstituted in 100 microliter of methanol, and 90 microliter is injected onto a reversed-phase column. The mobile phase is 32% acetonitrile in 0.75 M acetate buffer, pH 3.4, at a flow rate of 2 ml/min. The retention time of hydralazine p-anisaldehyde hydrazone is 6.5 min. The average coefficient of variation over 10-200 ng/ml is 5.5%, and the sensitivity limit is 5 ng/ml. Under the assay conditions, hydralazine pyruvic acid hydrazone, a known plasma metabolite of hydralazine, yields less than 0.1% hydralazine. Detectable plasma hydralazine levels of 5-20 ng/ml were found 10-30 min after a 0.5-mg/kg oral dose of hydralazine hydrochloride was given to a male volunteer.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 512893     DOI: 10.1002/jps.2600681123

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  4 in total

Review 1.  Clinical pharmacokinetics of hydralazine.

Authors:  T M Ludden; J L McNay; A M Shepherd; M S Lin
Journal:  Clin Pharmacokinet       Date:  1982 May-Jun       Impact factor: 6.447

2.  Effect of N-Acetyltransferase 2 Genotype on the Pharmacokinetics of Hydralazine During Pregnancy.

Authors:  Lyrialle W Han; Rachel J Ryu; Michael Cusumano; Thomas R Easterling; Brian R Phillips; Linda J Risler; Danny D Shen; Mary F Hebert
Journal:  J Clin Pharmacol       Date:  2019-06-30       Impact factor: 3.126

3.  Assay for hydralazine as its stable p-nitrobenzaldehyde hydrazone.

Authors:  H A Semple; Y K Tam; S Tin; R T Coutts
Journal:  Pharm Res       Date:  1988-06       Impact factor: 4.200

Review 4.  Clinical pharmacokinetics and therapeutic use of hydralazine in congestive heart failure.

Authors:  J P Mulrow; M H Crawford
Journal:  Clin Pharmacokinet       Date:  1989-02       Impact factor: 6.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.